Neuralstem, Inc. (NASDAQ:CUR) Files An 8-K Other EventsItem 8.01. Other Events.
On August 2, 2017, Neuralstem, Inc. (the “Company”) announced that it has been awarded a Phase 2 Small Business Innovation Research grant by the National Institutes of Health of up to $997,068 over two years to conduct preclinical research to evaluate the potential of NSI-189, a novel small molecule compound, for the prevention and treatment of diabetic neuropathy. A copy of the press release is attached to this report as Exhibit 99.01.
Item 9.01. Financial Statements and Exhibits.
| Exhibit No. | Description |
| 99.01 | Press Release dated August 2, 2017 |
Neuralstem, Inc. ExhibitEX-99.01 2 exh_9901.htm PRESS RELEASE EdgarFilingExhibit 99.01Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment of Diabetic Neuropathy GERMANTOWN,…To view the full exhibit click here
About Neuralstem, Inc. (NASDAQ:CUR)
Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company’s technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company’s NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.